生物Nxt解决方案公司迁至慕尼黑,以推进药物交付和神经退化疾病研究。 BioNxt Solutions relocates to Munich to advance drug delivery and neurodegenerative disease research.

BioNxt Solutions是一家以先进的药物供应为重点的生物科学公司,正在将其研究业务转移到德国慕尼黑的Gen-Plus CRDO。 BioNxt Solutions, a bioscience firm focused on advanced drug delivery, is moving its research operations to the Gen-Plus CRDO in Munich, Germany. 这一行动旨在加快药物交付、神经退化性疾病治疗和新的生物医学技术方面的项目。 This move aims to accelerate projects in drug delivery, neurodegenerative disease treatments, and new biomedical technologies. 1,000平方公尺的最新实验室将为BioNxt提供先进的技术和合作机会,加强研发,加速创新。 The 1,000-square-meter state-of-the-art lab will provide BioNxt with advanced technologies and opportunities for collaboration, enhancing their R&D and speeding up innovation.